Molecular Targets for the Treatment of Juvenile Myelomonocytic Leukemia
Significant advances in our understanding of the genetic defects and the pathogenesis of juvenile myelomonocytic leukemia (JMML) have been achieved in the last several years. The information gathered tremendously helps us in designing molecular targeted therapies for this otherwise fatal disease. Va...
Main Authors: | Liu, Xiaoling, Sabnis, Himalee, Bunting, Kevin D., Qu, Cheng-Kui |
---|---|
Format: | Online |
Language: | English |
Published: |
Hindawi Publishing Corporation
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226315/ |
Similar Items
-
The Genomic Landscape of Juvenile Myelomonocytic Leukemia
by: Stieglitz, Elliot, et al.
Published: (2015) -
Novel splicing-factor mutations in juvenile myelomonocytic leukemia
by: Takita, J, et al.
Published: (2012) -
Capillary nano-immunoassay for Akt 1/2/3 and 4EBP1 phosphorylation in acute myeloid leukemia
by: Sabnis, Himalee, et al.
Published: (2014) -
CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia
by: Fluhr, Silvia, et al.
Published: (2016) -
Deficiency of CREB and over expression of miR-183 in juvenile myelomonocytic leukemia
by: Liu, Y L, et al.
Published: (2013)